Coadministration of maraviroc and raltegravir (400 mg twice daily) decreased raltegravir AUC, C12 and Cmax decreased by 37%, 28% and 33%, respectively. Maraviroc AUC, C12 and Cmax decreased by 14%, 10% and 21%, respectively. These findings can be extended to raltegravir 1,200 mg once daily. No dose adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily) or maraviroc.
Isentress 600 mg Summary of Product Characteristics, Merck Sharp & Dohme Ltd, September 2021.

 

No clinically significant interaction seen. Coadministration of raltegravir (400 mg twice daily) and maraviroc (300 mg twice daily) decreased maraviroc AUC by 14% and decreased Cmax by 21%. Raltegravir AUC decreased by 37%, Cmax decreased by 33% and Cmin decreased by 28%. Maraviroc 300 mg twice daily and raltegravir can be coadministered without dose adjustment.
Celsentri Summary of Product Characteristics, ViiV Healthcare, September 2018.

 

Coadministration of raltegravir (400 mg twice daily) and maraviroc (300 mg twice daily) to 17 subjects decreased the Cmin, AUC and Cmax of maraviroc by 10%, 14% and 21%, respectively. Maraviroc decreased the Cmin and AUC of raltegravir by 27% and 37%, respectively, which is not clinically significant. The recommended dose of maraviroc when coadministered with raltegravir is 300 mg twice daily.
Selzentry Prescribing Information, ViiV Healthcare, July 2018.

 

The two-way pharmacokinetic interaction between maraviroc and raltegravir was assessed in a healthy volunteer, fixed sequence study with subjects receiving raltegravir (400 mg twice daily for 3 days) then maraviroc (300 mg twice daily for 6 days) followed by both drugs for 3 days. Drug concentrations were determined on the last day of dosing of each phase. Relative to individual monotherapy, co-administration decreased maraviroc mean AUC and Cmax by 14% and 20%, respectively, and decreased raltegravir mean AUC and Cmax by 37% and 33%, respectively. The authors suggest that the pharmacokinetic changes are unlikely to be of clinical significance and hence no dose adjustment will be necessary when the drugs are co-administered.
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Andrews E, Glue P, Fang J, et al. Br J Clin Pharmacol, 2010, 69: 51-57.